TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 14.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 529,271 shares of the biopharmaceutical company’s stock after purchasing an additional 66,911 shares during the period. Public Sector Pension Investment Board owned about 0.33% of TG Therapeutics worth $19,120,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TGTX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in TG Therapeutics by 1,221.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock worth $15,191,000 after buying an additional 390,137 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of TG Therapeutics by 21.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after acquiring an additional 345,059 shares during the last quarter. Marex Group plc bought a new stake in shares of TG Therapeutics during the 2nd quarter worth $10,017,000. Jump Financial LLC boosted its stake in shares of TG Therapeutics by 551.8% during the 2nd quarter. Jump Financial LLC now owns 320,022 shares of the biopharmaceutical company’s stock worth $11,518,000 after acquiring an additional 270,922 shares in the last quarter. Finally, Eventide Asset Management LLC grew its holdings in shares of TG Therapeutics by 32.8% in the 2nd quarter. Eventide Asset Management LLC now owns 954,531 shares of the biopharmaceutical company’s stock worth $34,354,000 after acquiring an additional 235,717 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Price Performance

Shares of TGTX opened at $28.50 on Friday. The business’s 50-day moving average is $30.09 and its 200-day moving average is $31.49. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. The company has a market capitalization of $4.52 billion, a price-to-earnings ratio of 10.25 and a beta of 1.85. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director directly owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.64% of the company’s stock.

Analysts Set New Price Targets

TGTX has been the subject of several analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. reduced their price objective on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.